Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer
Abstract Estrogen receptor (ER)-positive breast cancer (BC) is a prevalent and fatal cancer among women, and there is a need to identify molecules involved in the disease pathophysiology which could also serve as biomarkers for early detection. Detection of cancer markers in whole plasma produces ex...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cancer & Metabolism |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40170-025-00390-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284756504150016 |
|---|---|
| author | Yamama Abu Mohsen Rachel Twitto-Greenberg Anna Cohen Gil S Leichner Lidor Mahler Hofit Cohen Yehuda Kamari Aviv Shaish Ayelet Harari Alicia Leikin-Frenkel Efrat Glick Saar Tamar Geiger Sergey Malitsky Maxim Itkin Dror Harats Rom Keshet |
| author_facet | Yamama Abu Mohsen Rachel Twitto-Greenberg Anna Cohen Gil S Leichner Lidor Mahler Hofit Cohen Yehuda Kamari Aviv Shaish Ayelet Harari Alicia Leikin-Frenkel Efrat Glick Saar Tamar Geiger Sergey Malitsky Maxim Itkin Dror Harats Rom Keshet |
| author_sort | Yamama Abu Mohsen |
| collection | DOAJ |
| description | Abstract Estrogen receptor (ER)-positive breast cancer (BC) is a prevalent and fatal cancer among women, and there is a need to identify molecules involved in the disease pathophysiology which could also serve as biomarkers for early detection. Detection of cancer markers in whole plasma produces excessive information, and identifying important markers involved in cancer progression is challenging. We identified a BC-specific low-density lipoprotein (LDL) particle isolated by ultracentrifugation from the plasma of ER-positive BC patients. This LDL has an aberrant proteome and lipidome, significantly different from that of LDL from healthy women, including a high association with the pro-tumor chemokines CXCL4 and CXCL7, and an enrichment with the lipid subclasses phosphatidylethanolamine, ceramide, triglycerides, lysophosphatidylcholine, phosphatidylserine, phosphatidic acid, and sphingomyelin. In contrast, phosphatidylinositol species were significantly less abundant in LDL from tumor patients than in control. Moreover, BC-associated LDL has a distinct effect on macrophage phenotype, inducing an increased gene expression of IL1β, IL8 and CD206 and decreased gene expression of TNFα, a gene signature characteristic of tumor-associated macrophages (TAMs). This suggests that this formerly unrecognized form of LDL may represent LDL particles that are recruited by the tumor microenvironment to support tumor progression by inducing discrete subsets of TAMs. In conclusion, these data offer BC-associated LDL as an early biomarker detection platform for ER-positive BC. Furthermore, LDL-associated proteins and lipids that promote BC progression may also serve in the future as novel targets for BC therapies. |
| format | Article |
| id | doaj-art-436d2fcf680c4a83b3155502e84530c7 |
| institution | OA Journals |
| issn | 2049-3002 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer & Metabolism |
| spelling | doaj-art-436d2fcf680c4a83b3155502e84530c72025-08-20T01:47:29ZengBMCCancer & Metabolism2049-30022025-05-0113111010.1186/s40170-025-00390-6Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancerYamama Abu Mohsen0Rachel Twitto-Greenberg1Anna Cohen2Gil S Leichner3Lidor Mahler4Hofit Cohen5Yehuda Kamari6Aviv Shaish7Ayelet Harari8Alicia Leikin-Frenkel9Efrat Glick Saar10Tamar Geiger11Sergey Malitsky12Maxim Itkin13Dror Harats14Rom Keshet15The Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Wohl Institute for Translational Research, Sheba Medical CenterWeizmann Institute of ScienceWeizmann Institute of ScienceWeizmann Institute of ScienceThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterThe Bert W. Strassburger Metabolic Center for Preventive Medicine, Sheba Medical CenterAbstract Estrogen receptor (ER)-positive breast cancer (BC) is a prevalent and fatal cancer among women, and there is a need to identify molecules involved in the disease pathophysiology which could also serve as biomarkers for early detection. Detection of cancer markers in whole plasma produces excessive information, and identifying important markers involved in cancer progression is challenging. We identified a BC-specific low-density lipoprotein (LDL) particle isolated by ultracentrifugation from the plasma of ER-positive BC patients. This LDL has an aberrant proteome and lipidome, significantly different from that of LDL from healthy women, including a high association with the pro-tumor chemokines CXCL4 and CXCL7, and an enrichment with the lipid subclasses phosphatidylethanolamine, ceramide, triglycerides, lysophosphatidylcholine, phosphatidylserine, phosphatidic acid, and sphingomyelin. In contrast, phosphatidylinositol species were significantly less abundant in LDL from tumor patients than in control. Moreover, BC-associated LDL has a distinct effect on macrophage phenotype, inducing an increased gene expression of IL1β, IL8 and CD206 and decreased gene expression of TNFα, a gene signature characteristic of tumor-associated macrophages (TAMs). This suggests that this formerly unrecognized form of LDL may represent LDL particles that are recruited by the tumor microenvironment to support tumor progression by inducing discrete subsets of TAMs. In conclusion, these data offer BC-associated LDL as an early biomarker detection platform for ER-positive BC. Furthermore, LDL-associated proteins and lipids that promote BC progression may also serve in the future as novel targets for BC therapies.https://doi.org/10.1186/s40170-025-00390-6Low density lipoproteinBreast cancerProteomicsLipidomicsMacrophages |
| spellingShingle | Yamama Abu Mohsen Rachel Twitto-Greenberg Anna Cohen Gil S Leichner Lidor Mahler Hofit Cohen Yehuda Kamari Aviv Shaish Ayelet Harari Alicia Leikin-Frenkel Efrat Glick Saar Tamar Geiger Sergey Malitsky Maxim Itkin Dror Harats Rom Keshet Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer Cancer & Metabolism Low density lipoprotein Breast cancer Proteomics Lipidomics Macrophages |
| title | Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer |
| title_full | Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer |
| title_fullStr | Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer |
| title_full_unstemmed | Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer |
| title_short | Proteomic and lipidomic analysis of low-density lipoprotein identifies potential biomarkers of early estrogen receptor-positive breast cancer |
| title_sort | proteomic and lipidomic analysis of low density lipoprotein identifies potential biomarkers of early estrogen receptor positive breast cancer |
| topic | Low density lipoprotein Breast cancer Proteomics Lipidomics Macrophages |
| url | https://doi.org/10.1186/s40170-025-00390-6 |
| work_keys_str_mv | AT yamamaabumohsen proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT racheltwittogreenberg proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT annacohen proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT gilsleichner proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT lidormahler proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT hofitcohen proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT yehudakamari proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT avivshaish proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT ayeletharari proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT alicialeikinfrenkel proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT efratglicksaar proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT tamargeiger proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT sergeymalitsky proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT maximitkin proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT drorharats proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer AT romkeshet proteomicandlipidomicanalysisoflowdensitylipoproteinidentifiespotentialbiomarkersofearlyestrogenreceptorpositivebreastcancer |